



Quick reference guide to apixaban [Corrigendum]

Hurst KV, O'Callaghan JM, Handa A. *Vascular Health and Risk Management*. 2017;13 263–267.

On page 264, Table 2 states that the apixaban dose should be reduced in patients with mild hepatic impairment and that it is not indicated in patients with moderate-to-severe hepatic impairment. This is also stated in the text to the left of that table.

The authors amend this to:

Apixaban dose adjustment is not required in patients with mild or moderate hepatic impairment, however it should be used with caution in these patients and dose adjustment may be needed. Apixaban is not recommended in patients with severe hepatic impairment.

Vascular Health and Risk Management downloaded from <https://www.dovepress.com/> by 137.108.70.14 on 24-Jan-2020
For personal use only.

Vascular Health and Risk Management

Dovepress

Publish your work in this journal

Vascular Health and Risk Management is an international, peer-reviewed journal of therapeutics and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of

metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/vascular-health-and-risk-management-journal>

